Genentech Inc. is partnering with Seattle-based Adaptive Biotechnologies Corp. to develop a new type of cell therapy for solid cancers targeting individual's tumor-specific proteins, or neoantigens.
Adaptive Biotechnologies and Biogen Idec are together searching for immunological biomarkers for difficult-to-treat autoimmune diseases, the firms said. Financial terms were not disclosed. Under the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results